CompanyHUMANasdaqDurham, NC

Humacyte, Inc.

Humacyte develops acellular tissue engineered vessels (ATEVs) to treat vascular trauma, arteriovenous access for hemodialysis, and peripheral artery disease.

Stories only

SEC EDGAR ClinicalTrials.gov symvess.com

8-KSep 28Latest SEC filing

Sep 28Latest story

September 2026

Humacyte adds Scott Coward and Paul Kuznik to board of directors

Sep 28Peopleacellular tissue engineered vessel Humacyte, Inc.

August 2026

Humacyte registers two Symvess trials: adolescent Phase 3 study and adult Phase 4 real-world study

Aug 13Weekly roundup, 2 itemsacellular tissue engineered vessel Humacyte, Inc.

Humacyte reports ATEV outperformed AV fistula in Phase 3 dialysis trial

Aug 12Quarterly updateacellular tissue engineered vessel Humacyte, Inc.

July 2026

Humacyte posts trauma trial results, registers new Phase 2a coronary CTEV study for CABG

Jul 29Weekly roundup, 2 itemsacellular tissue engineered vessel Humacyte, Inc.